Inspire Investing LLC Grows Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Inspire Investing LLC grew its holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 68.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 73,160 shares of the biopharmaceutical company’s stock after purchasing an additional 29,645 shares during the period. Inspire Investing LLC’s holdings in Revance Therapeutics were worth $360,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of RVNC. Clarity Capital Partners LLC purchased a new stake in Revance Therapeutics in the first quarter worth $59,000. Tower Research Capital LLC TRC grew its position in shares of Revance Therapeutics by 626.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,823 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 5,884 shares in the last quarter. Quest Partners LLC bought a new position in shares of Revance Therapeutics during the 4th quarter worth $84,000. China Universal Asset Management Co. Ltd. grew its position in shares of Revance Therapeutics by 67.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 16,981 shares of the biopharmaceutical company’s stock worth $84,000 after buying an additional 6,826 shares in the last quarter. Finally, Victory Capital Management Inc. bought a new position in shares of Revance Therapeutics during the 4th quarter worth $93,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Price Performance

Shares of RVNC stock opened at $4.18 on Wednesday. The company has a market cap of $436.60 million, a P/E ratio of -1.17 and a beta of 0.98. The stock’s 50-day moving average is $2.97 and its 200 day moving average is $4.53. Revance Therapeutics, Inc. has a 1-year low of $2.30 and a 1-year high of $24.87.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.12. The business had revenue of $51.94 million during the quarter, compared to analyst estimates of $55.64 million. On average, analysts anticipate that Revance Therapeutics, Inc. will post -1.83 EPS for the current year.

Wall Street Analyst Weigh In

RVNC has been the topic of a number of recent research reports. The Goldman Sachs Group dropped their price target on Revance Therapeutics from $9.00 to $8.00 and set a “neutral” rating on the stock in a research report on Monday, May 13th. Piper Sandler reissued an “overweight” rating and set a $11.00 price target (down previously from $20.00) on shares of Revance Therapeutics in a research report on Friday, May 10th. Mizuho dropped their price target on Revance Therapeutics from $9.00 to $8.00 and set a “neutral” rating on the stock in a research report on Friday, May 10th. HC Wainwright dropped their price objective on Revance Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, May 13th. Finally, Needham & Company LLC dropped their price objective on Revance Therapeutics from $18.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $11.50.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.